Cancer
| 4 min read
Transgene expands a duck-cell-line license as its personalized cancer vaccines advance deeper into the clinic
| 4 min read
A newly certified DPYD genotyping assay gives oncologists a validated way to flag chemotherapy toxicity risk before treatment starts
| 3 min read
Researchers at Erasmus MC and Apeximmune independently identified PLA2G2D as a potential new target for restoring antitumor T cell responses.
| 5 min read
The science behind personalized mRNA cancer vaccines is working. Building a different drug for every patient, at scale, is the real fight.
| 2 min read
The newly discovered cells protect the tumor by recruiting regulatory T cells to create an immunosuppressive environment.
| 3 min read
A logic-gated platform is expanding what's druggable in antibody-drug conjugate development by pairing antigens that cancer cells co-express but normal tissue does not.
| 6 min read
Bacteria have been linked to cancer treatment for more than a century. Now researchers are trying to turn them into actual therapies.
| 6 min read
As in vivo CAR T gains momentum, developers are finding new ways to make ex vivo manufacturing faster, more reproducible, and scalable.
| 3 min read
The new approach combined digital pathology with spatial proteomics to uncover the secrets of metastasis and personalized treatment options.
| 4 min read
The Nurix and Roche partnership on bexobrutideg is the latest sign that targeted protein degradation is moving well beyond oncology.
| 2 min read
A new alternative approach to antibody-drug conjugates takes advantage of cancer cells’ need for fuel — first by encouraging them to overdose on glucose and then by blocking its backup source of fat.
| 5 min read
Wobble Genomics is using long-read RNA sequencing to reveal the molecular signals that determine whether a cancer treatment will work.
